

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

14114.0346U2

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/890551

INTERNATIONAL APPLICATION NO.
PCT/US00/02498

INTERNATIONAL FILING DATE
1 February 2000

PRIORITY DATE CLAIMED
3 February 1999

TITLE OF INVENTION

METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O

APPLICANT(S) FOR DO/EO/US

Lal et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail **EL348125847US**
20. ☒ Other items or information:

Notification of the Recording of a Change dated 17 October 2000
 Notification of the Recording of a Change dated 20 February 2001
 Notification of the Recording of a Change dated 8 March 2001
 Notification of the Recording of a Change dated 8 March 2001
 Notification of the Recording of a Change dated 29 June 2001
 Sequence Listing
 Sequence Listing Diskette
 Return Postcard

EL348125847US

U.S. APPLICATION NO. (IF KNOWN) SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/US00/02498

14114.0346U2

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS PTO USE ONLY**

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	19 - 20 =	0	x \$18.00
Independent claims	3 - 3 =	0	x \$80.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>
TOTAL OF ABOVE CALCULATIONS			=
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>
SUBTOTAL			=
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			+
TOTAL NATIONAL FEE			=
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>
TOTAL FEES ENCLOSED			=
			Amount to be:
			refunded
			charged

\$0.00

\$0.00

\$0.00

\$860.00

\$0.00

\$860.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

\$860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00

\$860.00

Amount to be:

refunded

charged

☒ A check in the amount of \$860.00 to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☐ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. _____ A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mary L. Miller, Ph.D.
NEEDLE & ROSENBERG, P.C.
1200 Cander Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303

SIGNATURE

Mary L. Miller

NAME

39,303

REGISTRATION NUMBER

DATE

5

10

**METHODS AND REAGENTS FOR MOLECULAR
DETECTION OF HIV-1 GROUPS M, N AND O**

15

This invention was made at the Centers for Disease Control and Prevention. Therefore, the United States Government has certain rights in this invention.

FIELD OF THE INVENTION

20

The present invention relates to the fields of virology and molecular biology and provides methods and reagents for detecting human immunodeficiency virus (HIV) in a biological sample. More particularly, the methods detect the presence of HIV-1 envelope groups M, N and O by amplifying HIV-1 nucleic acid molecules in a biological sample using HIV-1 primers.

25

BACKGROUND OF THE INVENTION

30

35

One of the most ravaging diseases of the late twentieth century has been acquired immunodeficiency syndrome (AIDS), caused by infection with HIV. There are several known strains of HIV including HIV-1, a collective term referring to several strains isolated in Europe or America, and HIV-2, a strain endemic in many West African countries. HIV-1 is classified by phylogenetic analysis into three groups, group M (major), group O (outlier) and a new variant of HIV-1, designated group N, that has been identified with its epicenter in Cameroon (Simon *et al.*, *Nat Med* 4:1032-1037 (1998)). All three HIV-1 groups cause AIDS.

09890551-080101

Group M contains at least ten subtypes, referred to as A through J, based on the sequence heterogeneity of the envelope region. Group O includes most divergent viruses that do not cluster with group M strains. Group N includes viruses that are distinct from HIV-1 groups M and O. For example, detailed genetic analyses have placed the origin of the YBF30 virus of group N far from that of group O, somewhere between group M and simian immunodeficiency virus (SIV) cpz-gabs. The worldwide distribution of various group M HIV-1 subtypes is diverse, with subtype B being most prevalent in North America and Europe and subtype A being most prevalent in Africa. Whereas most subtypes are common in Central Africa, other areas have restricted distribution of genotypes; for instance subtype E is highly prevalent in Thailand, subtype C is common in India and South Africa, and subtype F is prevalent in Romania, Brazil and Argentina. Type O infections have been identified in the West Central African countries of Cameroon and neighboring countries, such as Equatorial Guinea and Gabon. The spread of group O infections to Europe and more recently to the United States has been documented, although all patients have had links to West Central Africa.

The wide divergence of the HIV-1 group O viruses has created serious public health concerns regarding the safety of the blood supply. Reports by Eberle *et al.*, *J. Virol. Methods* 67:85-91 (1997), and Loussert-Ajaka *et al.*, *J. Virol.* 69:5640-5649 (1995) have indicated that serologic screening assays based on group M viruses, such as HIV-1 subtype B-based assays, may be unable to consistently detect group O infected blood. The residual risk of HIV-transmission from transfusions of blood screened using current antibody and antigen tests is estimated by scientists such as Schreiber *et al.*, *New Engl. J. of Med.* 334:1685 (1996), to be two blood donations per million in the United States. The prevalence of group O infections in Africa and the spread of type O infections to other continents emphasizes the need for improved screening of the international blood supply. Ideally, improved screening assays should be

highly sensitive in detecting all variants of HIV-1 group M, N and O contamination in donor blood. In addition, the screening assays should be able to detect plasma viremia, thereby allowing for earlier detection of HIV-1 and reducing blood transfusion infections associated with "window period" cases in which an individual is infected with the virus, but has not yet produced detectable levels of antibody against the virus.

Most commercially available HIV diagnostic assays are based on the detection of anti-HIV antibodies and antigens. However, several reports have shown that antibodies against some variants of HIV-1 group O are not reliably detected by these assays, primarily due to diversity in the immunodominant regions of HIV-1. If undiagnosed, these HIV-infected individuals may engage in activities or conduct resulting in the spread of the virus. In addition, these undiagnosed individuals may remain untreated, allowing the disease to progress until the onset of immunodeficiency symptoms.

Some of the currently available HIV diagnostic tests and many of the viral load assay tests used to assess the success of therapeutic treatment are nucleic acid-based. (Respass *et al.*, *J. Clin. Microbiol.* 35:1284-1286 (1997)). Scientists have reported that these nucleic acid-based assays exhibit reduced sensitivities for non-subtype B HIV isolates (Alaeus *et al.*, *AIDS* 11:859-865 (1997)). Since therapeutic regimens are evaluated and monitored by analyzing viral loads, the inability of current assays to accurately quantitate the viral load of all subtypes is a detriment to successful therapy (Cavert, *AIDS* 12 (Suppl. A):S27 (1998)).

While several molecular detection assays have been described for the detection of proviral DNA from peripheral blood (Respass *et al.*, *J. Clin. Micro.* 35:1284-1286 (1997); Fransen *et al.*, *Mol. Cellular Probes* 8:317-322 (1994); Loussert-Ajaka *et al.*, *Lancet* 346:912-913 (1995)), none can amplify both group M and O HIV-1 strains from plasma using a single assay.

Therefore, what are needed are methods for detecting group M, N and O HIV infections in blood plasma, serum or other biological samples using a single assay and methods for distinguishing between group M, N and O infections in biological samples. In addition, highly sensitive qualitative and quantitative assays for HIV-1 group M, N and O viruses are needed.

SUMMARY OF THE INVENTION

Highly sensitive methods and reagents for the molecular detection of group M, group N and group O nucleic acid molecules in biological samples are provided. The reagents include nucleic acid probes or primers that hybridize to group M, group N and group O HIV-1 nucleic acids and also include probes or primers that hybridize to SIV from chimpanzees (SIVcpz) that are closely related to HIV-1 nucleic acids. The preferred nucleic acid probes and primers have the sequences set forth in SEQ ID NOS: 1-9. The methods employ the reagents to amplify and detect group M, group N and group O HIV-1 nucleic acid sequences and are useful for early diagnostic detection of group M, group N and group O infection in a patient. The methods and reagents can therefore be used to screen blood donors and donated blood for HIV contamination. The assay can also be modified for quantitative viral load determination of all HIV-1 strains. The methods and reagents are also useful for monitoring the success of particular antiviral therapies for patients receiving therapy and can be used to screen antiviral compounds for efficacy against HIV.

The methods described herein, also referred to herein as assays, employ a generic probe or a primer set based on a conserved immunodominant region of the HIV-1 transmembrane protein gp41 and a viral DNA integrating enzyme, integrase (IN). The assays are highly sensitive in detecting HIV-1 positive specimens of diverse geographic origin representing different subtypes of HIV-1 group M, as well as HIV-1 group O and the most recently discovered group N. In addition, the assays are useful for detecting viral RNA from HIV-

1 seropositive specimens with plasma copy numbers below
detection by commercially available viral load assays. The highly
sensitive assays are useful for early detection of HIV-1, as well as
viral load determination in clinical specimens from all HIV-1
infections regardless of genotypes and geographic origin. The
generic probe or primer set is useful with known methods of
quantitation of HIV-1 RNA in biological samples, such as plasma,
for sensitive quantitation that is independent from genotype and
geographic origin.

In accordance with the methods, a patient or donor
sample is combined with one or more of the generic nucleic acid
primers or probes described herein under hybridization
conditions for selective hybridization of the probe or primer to
HIV-1 nucleic acid molecules in the sample. The probes or
primers hybridize to viral RNA or DNA present in the sample
from both HIV-1 groups M and O. Additional probes or
primers are included in the assay for the detection of group N
HIV-1 and SIVcpz nucleic acids. Hybridization of the probes is
detected by nucleic acid detection methods known to those
skilled in the art. Hybridization of the primer set results in
amplification of the HIV-1 RNA or DNA present in the sample
using techniques such as reverse transcription (RT) and the
polymerase chain reaction (PCR). The amplified viral nucleic
acids (RNA and DNA) are then detected using known
techniques

The HIV-1 RNA/DNA detection methods are highly
sensitive and, under optimal conditions, can be used to detect
HIV-1 positive plasma and cell samples greater than 96% of the
time. Additional sensitivity is achieved by subsequently
employing additional amplification steps, such as amplification
using a different gene region, to achieve as much as 100%
detection of HIV-1 in an HIV-1 positive sample.

The use of the probes and primers in the assays described
herein provide one or more of the following advantages. The
assays provide highly sensitive as well as specific assays for
diagnostic detection of HIV-1 group M, N and O viruses. The

sequence analysis of amplified products permits phylogenetic clustering of HIV-1 strains. Use of the assays allows early detection of HIV-1 viremia during "window period" cases, and the methods can be adapted as quantitative viral load assays for detection of both group M and O, and optionally, group N HIV-1 strains.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the detection of diverse strains of HIV-1 group M, N and O and SIVcpz using gp41 and integrase primer sets. Known copy numbers (10 and 5 copies per PCR reaction, abbreviated as A10 and A5, etc. for each subtype) of reference clones for HIV-1 group M subtype A (92UG037.1), B (YU2), C (92BR025.8), D (94UG114.1), A/E (90CF402.8), F(93BR020.1), A/G (92NG003.1), and H (90CF056.1) amplified by gp41 (Panel A) and integrase (Panel C) are shown. Amplification of viral RNA and/or DNA representing HIV-1 group O (BCF01, 02, 03, and 3012), group N (YBF30), and SIVcpz (GAB1, US, and ANT) by primer pairs gp41 (Panel B) and integrase (Panel D) are also depicted.

Figures 2A and 2B show the phylogenetic position of newly sequenced (in bold) and previously reported HIV-1 and SIVcpz strains in subgenomic *pol* (IN) (A) and *env* (gp41) (B) regions. Figure 2A depicts the relationships of sequences derived from the amplified integrase (IN) region, and 2B represents the gp41 region. The topology shows an overall branching order consistent with phylogenies previously reported for full length *pol* and *env* sequences. Trees were derived from nucleotide sequence alignments (consensus lengths of 183 bp and 348 bp, respectively) using the neighbor-joining method. Horizontal branch lengths are drawn to scale, with the bar indicating 0.10 nucleotide substitutions per site. Numbers at the nodes indicate the percentage of bootstrap values (out of 500) in which the cluster to the right is supported (only values equal or above 70% are shown). Brackets identify known HIV-1 (groups

M, N and O) and SIVcpz (*Pan troglodytes troglodytes* and *Pan troglodytes schweinfurthii*) viral lineages.

DETAILED DESCRIPTION OF THE INVENTION

5 Reagents and methods for detecting both HIV-1 groups M and O, and optionally, HIV-1 group N and SIVcpz are provided. Kits containing the reagents for use in conducting the methods are also provided. The reagents are nucleic acid probes or primers for the replication, amplification and subsequent
10 detection of HIV-1 groups M, N and O in a biological sample. The reagents also include nucleic acid probes or primers that hybridize to, and distinguish genetically diverse variants of SIV from chimpanzees that are closely related to HIV nucleic acids, namely SIVcpzGAB, SIVcpzANT and SIVcpzUS. The assays and kits employ the probes for the direct detection of HIV-1 and
15 employ the primers for HIV-1 nucleic acid amplification using amplification techniques such as RT and PCR. The assays are useful for diagnosing HIV-1 group M, HIV-1 group N, or HIV-1 group O infection in a patient. Due to the high sensitivity of the assays, small concentrations of HIV in a biological sample can be
20 detected, which allows diagnosis at an early stage of infection. The assays are also useful for detecting HIV-1 contamination in a biological fluid such as blood. The assays are qualitative or quantitative and are therefore useful for viral load determinations
25 of HIV-1 groups M, N or O in a patient undergoing treatment against HIV-1. Viral load determinations can be used to monitor the progress of the treatment regimen or the development of drug resistance and can be used to predict disease progression.

30 Definitions

 The terms "a", "an" and "the" as used herein are defined to mean "one or more" and include the plural unless the context is inappropriate.

35 As used herein, the term "complementary DNA primer" means an oligonucleotide which anneals to an RNA molecule in a particular orientation to allow for the synthesis of a nascent

DNA strand in the presence of the enzyme reverse transcriptase (RT) under the conditions described herein. Also as used herein, the "condition" or "conditions" under which a DNA strand is synthesized include the presence of nucleotides, cations and appropriate buffering agents in amounts and at temperatures such that the RNA molecule and the DNA primer will anneal and oligonucleotides will be incorporated into a synthesized DNA strand. The described conditions have been optimized from other known reverse transcriptase/complementary DNA (RT/cDNA) synthesis protocols. It is generally known that other conditions can be established for optimization of a particular RT reaction on the basis of protocols well known to one of ordinary skill in the art.

As used herein, the terms "primer pair" and "primer set" refers to two primers, one having a forward designation and the other having a reverse designation relative to their respective orientations on a double-stranded DNA molecule which consists of a sense and antisense sequence, such that under the amplification conditions described herein, the forward primer anneals to and primes amplification of the sense sequence and the reverse primer anneals to and primes amplification of the antisense sequence. Primers can be selected for use in the amplification reaction on the basis of having less than 50% G-C content, having minimal complementarity with other primers in the reaction (to minimize the formation of primer dimers) and having melting temperature (T_m) values with the range of reaction temperatures appropriate for the amplification method, preferably PCR. In addition, primers can be selected to anneal with specific regions of the RNA template such that the resulting DNA amplification product ranges in size from 100 to 500 base pairs in length and most preferably around 300 base pairs in length. For example, in the conditions described above, the primer pair can consist of the oligonucleotide of SEQ ID NO:1 (GP40F1) as the forward primer and the oligonucleotide of SEQ ID NO:2 (GP41R1) as the reverse primer as describe in more detail below.

As used herein, the terms "detecting" or "detection" of the amplified DNA refers to qualitatively or quantitatively determining the presence of the amplified DNA strand. The amplification of the synthesized DNA or direct detection of viral DNA can be detected by any method for the detection of DNA known in the art. For example, detection of the amplified DNA can be by Southern blot hybridization assay, by visualization of DNA amplification products of specific molecular weight on ethidium bromide stained agarose gels, by measurement of the incorporation of radiolabeled nucleotides into the synthesized DNA strand by autoradiography or scintillation measurement, by ELISA modified for the capture of a detectable moiety bound to the amplified DNA, or any other detection method known to one of ordinary skill in the art. The preferred detection method is by hybridization of the amplified DNA to an internal specific oligoprobe using techniques such as ELISA, Southern blot hybridization or similar methods.

By "isolated" is meant nucleic acid free from at least some of the components with which it naturally occurs.

By "selective" or "selectively" is meant a sequence that does not hybridize with other nucleic acids to prevent adequate determination of an HIV-1 infection, depending upon the intended result. As used herein to describe nucleic acids, the term "selectively hybridizes" excludes the occasional randomly hybridizing nucleic acids, and thus has the same meaning as "specifically hybridizing".

By "probe" is meant a nucleic acid sequence that can be used for selective hybridization with complementary nucleic acid sequences for their detection. The probe can vary in length from about 5 to 100 nucleotides, preferably from about 10 to 50 nucleotides, most preferably about 25 nucleotides. The terms "probe" and "primer" are used interchangeably herein with the understanding that probes are used to directly or indirectly detect a nucleic acid whereas primers are used to amplify the nucleic acid and the amplified product is then detected. Generally, "probes" are labeled with a detectable label and

“primers” are utilized in a set of two to hybridize to two different segments of a target nucleic acid molecule to amplify the sequence between those two segments.

As used herein, the term “highly conserved region” refers to those regions on a DNA or RNA molecule that are identical or nearly identical in related species or among various sub-species.

HIV-1 Group M, N and O Probes or Primers

The probes or primers used in the assays described herein are oligonucleotides, each having a nucleic acid sequence that specifically or selectively hybridizes under stringent hybridization conditions for selective hybridization to the complimentary, or opposite, strand of a highly conserved region of the nucleic acid molecule of the HIV-1 between nucleotide positions 7746 and 8459 of the HXB2 strain, for the *env* product, gp41, and between nucleotide positions 4596 and 5080 for the *pol* product, integrase. (GenBank Accession No. K03455; see the website <http://hiv-web.lanl.gov/NUM-HXB2/HXB2.MAIN.html>). In a preferred embodiment, the probes or primers within this region selectively hybridize with all group M and O HIV-1 nucleic acids. In an alternative preferred embodiment, the probes or primers selectively hybridize with all group M, N and O HIV-1 nucleic acids and with chimpanzee SIV nucleic acids.

Preferably, the primers hybridize to a highly conserved region of the nucleic acid molecule encoding the *env* gene protein of the HIV-1 between the following nucleotide positions of the HXB2 strain: 7746 to 7772; 7817 to 7844; 8220 to 8258; and 8432 to 8459.

More preferably, the primers hybridize to a highly conserved region of the nucleic acid molecule encoding the gp41 protein of the HIV-1 between the following nucleotide positions of the HXB2 strain: 7789 to 7816; 8347 to 8374; 7850 to 7879; 8265 to 8294; and 8281 to 8310.

In an alternative preferred embodiment, the primers hybridize to a highly conserved region of the nucleic acid

molecule encoding the integrase gene protein of HIV-1 between the following nucleotide positions of the HXB2 strain: 4596 to 4625; 5051 to 5080; 4724 to 4753; and 4956 to 4984.

Hybridization may be achieved under various temperatures and conditions, according to the temperature of dissociation (Td) of the molecules being hybridized and the stringency required for specific binding. The molecules can be hybridized to one another in any order or preferably at the same time. Reaction conditions for hybridization of an oligonucleotide, or polynucleotide, to a nucleic acid sequence vary from oligonucleotide to oligonucleotide, depending on factors such as oligonucleotide length, the number of G and C nucleotides, and the composition of the buffer utilized in the hybridization reaction. Moderately stringent hybridization conditions are generally understood by those skilled in the art as conditions approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA. Higher specificity is generally achieved by employing incubation conditions having higher temperatures, in other words more stringent conditions. Under extremely stringent hybridization conditions, only oligomers that are completely complementary to each other will remain hybridized to each other. In general, the longer the sequence or higher the G and C content, the higher the temperature required or salt concentration permitted. Chapter 11 of the well-known laboratory manual of Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1989), describes hybridization conditions for oligonucleotide probes and primers in great detail, including a description of the factors involved and the level of stringency necessary to guarantee hybridization with specificity. Hybridization techniques are well-documented in the scientific literature; one set of possible conditions is exemplified below.

Each primer is preferably a DNA molecule, most preferably a cDNA molecule, having a length of 18 to 40 nucleotides. More preferably, the length of the primer is 25 to 35

nucleotides. The most preferred primer length is 27 to 29 nucleotides. Depending on the length of the primer, the target hybridization region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions.

The selectively hybridizing nucleic acid primers described herein have at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, and 99% complementarity with the segment of the sequence to which they hybridize. It will be understood that a combination of the probes and primers described herein can be combined to enable the detection of groups M, N and O HIV-1.

The primers are ideally used in primer pairs, containing a forward primer and a reverse primer, that hybridize to two different regions of HIV-1 nucleic acid molecule from groups M, N, and O within the highly conserved region of the *env* gene, particularly the small gp41 gene, or the *pol* gene, particularly the integrase genes. In the presence of reverse transcriptase, the HIV-1 nucleic acid sequence located between the hybridization regions is replicated and thereby amplified and subsequently detected. The length of the HIV-1 nucleic acid sequence being replicated is preferably 400 to 600 nucleotides. Nested primer pairs, in which a second primer pair hybridizes to and replicates a portion of the nucleic acid sequence replicated by a first primer pair, are useful for increasing amplification and thereby enhancing the specificity and sensitivity of an assay in which the primers are employed.

A preferred forward primer of a preferred primer pair for the detection of group M, N and O HIV-1 is the oligonucleotide of SEQ ID NO:1 (GP40F1), which has the following nucleotide sequence, or conservative substitutions thereof:

5' TCTTAGGAGCAGCAGGAAGCACTATGGG 3'

A preferred reverse primer of the preferred primer pair for the detection of group M, N and O HIV-1 is the oligonucleotide of SEQ ID NO:2 (GP41R1), which has the

following nucleotide sequence, or conservative substitutions thereof:

5' AACGACAAAGGTGAGTATCCCTGCCTAA 3'

5

For nested amplification for the detection of group M, N and O HIV-1, a preferred forward primer is the oligonucleotide of SEQ ID NO:3 (GP46F2), which has the following nucleotide sequence, or conservative substitutions thereof:

10

5' ACAATTATTGTCTGGTATAGTGCAACAGCA 3'

A preferred reverse primer for the detection of group M, N and O HIV-1 for nested amplification is the oligonucleotide of SEQ ID NO:4: (GP47R2), which has the following nucleotide sequence:

15

5' TTAAACCTATCAAGCCTCCTACTATCATTA 3'

20

An alternate reverse primer for the detection of group N HIV-1 and SIVcpz is the oligonucleotide of SEQ ID NO:5 (GP48R2), which has the following nucleotide sequence, or conservative substitutions thereof:

25

5' TCCTACTATCTTAATGAATATTTTATATA 3'

30

Another preferred forward primer of a preferred primer pair for the detection of group M, N and O HIV-1 is the oligonucleotide of SEQ ID No: 6 (INTF1), which has the following nucleotide sequence, or conservative substitutions thereof:

5'AGTGCTGCAGTTAAGGCAGCCTGTTGGTGG3'

35

TOP SECRET

Another preferred reverse primer of the preferred primer pair for the detection of group M, N and O HIV-1 is the oligonucleotide of SEQ ID NO: 7 (INTR1), which has the following nucleotide sequence, or conservative substitutions thereof:

5'CTACCTGCCAGACAATCATCACCTGCCATC3'

For nested amplification for the detection of group M, N and O HIV-1, another preferred forward primer is the oligonucleotide of SEQ ID NO: 8 (INTF2), which has the following nucleotide sequence, or conservative substitutions thereof:

5'AAGAGATCAAGCTGAACATCTTAAGACAGC3'

Another preferred reverse primer for the detection of group M, N and O HIV-1 for nested amplification is the oligonucleotide of SEQ ID NO: 9 (INTR2), which has the following nucleotide sequence:

5'TGTATTACTACTGCCCCCTTCACCTTTCCA3'

It will be understood by those skilled in the art that oligonucleotides homologous to the primers described above will selectively hybridize, under hybridization conditions as described above, to the highly conserved region of the nucleic acid molecule encoding either the *env* gene protein, or to the *pol* gene protein of HIV-1, particularly the integrase protein. Preferably, the oligonucleotides have 90% or greater homology to the specific probe and primer sequences provided above and in the Sequence Listing. Homology is determined using a sequence/pattern computer program such as the BLAST™ 2.0 (gapped) sequence/pattern computer program or the CLUSTAL™ sequence alignment program using conditions and parameters well known to those skilled in the art. Therefore, these homologous primers are useful for the amplification and subsequent detection of HIV-1 nucleic acid molecules in a

biological sample as described below and are therefore included within the scope of the present invention.

The probes and primers of SEQ ID NOS: 1-9 individually, in primer pairs, and in combination, (and those as modified by the above conditions) hybridize or anneal to all known HIV-1 group M, N SIV_{op2}, nucleic acid molecules and SIVcpz are therefore useful for the detection of these HIV-1 groups in biological samples obtained from various geographic locations throughout the world. In addition, the probes and primers are useful for both qualitative and quantitative detection of all known group M, N and O HIV-1 strains and may be useful for the detection of unknown group M, N and O HIV-1 strains. The ability of one or two sets of primers to detect such divergent subtypes of HIV-1 is highly unexpected, because, while the nucleotide region chosen for amplification is highly conserved, the same gp41 region shows considerable divergence between the immunodominant epitope of group M and O. Therefore, most serologic assays based on the detection of antibodies to the gp41 region prior to this discovery have been required to include a group O-specific peptide to enhance antibody detection as described by Loussert-Ajaka *et al.*, *J. Virol.* 69:5640-5649 (1995) and Eberle *et al.*, *J. Virol. Methods* 67:85-91 (1997).

It will be understood by those skilled in the art that the oligonucleotides described herein could be labeled with a detectable label, as described below, and used directly as HIV-1 group M and O nucleic acid detection probes in accordance with known methods.

Assay for Detecting HIV-1 Groups M, N and O

The probes and primers described above are useful in assays to detect, diagnose, quantify and monitor HIV-1 group M, N and O nucleic acids in a biological sample. In accordance with the method, one or more of the probes or primers, or one or more primer pairs, is combined with a biological sample to form an incubation mixture. The incubation mixture is reacted or incubated under conditions whereby the nucleic acid of the HIV-

1 genome, including both RNA and DNA, and the primer will hybridize or anneal. An oligonucleotide strand is synthesized as an extension from the primer in the presence of a polymerase. The extension product is amplified using a second primer and suitable nucleic acid amplification reagents and conditions. The amplified product is then detected in accordance with methods known to those skilled in the art. Detection of the amplified nucleic acid indicates the presence of HIV-1 group M, N or O nucleic acids (DNA or RNA) in the biological sample.

The biological sample to be tested or analyzed may be taken from an individual, such as a wound, blood, secretion, tissue, bone, muscle, cartilage, or skin sample, or may be a laboratory research sample such as a cell culture supernatant, viral isolate or viral clones. The sample may be obtained from any biological source and is preferably taken from a human or animal, particularly a chimpanzee, capable of being infected with or harboring HIV-1. For example, the sample may be a biological fluid, such as whole blood, blood serum, blood plasma, urine, semen, saliva, sputum, cerebrospinal fluid, lacrimal fluid, lymph fluid, tissue culture fluid, ascites fluid, synovial fluid, pleural fluid, and the like. The preferred biological sample is a biological fluid from which cells can be removed or collected. The most preferred samples are blood plasma, serum and peripheral blood mononuclear cells isolated from entire blood.

The sample is collected or obtained using methods well known to those skilled in the art and may be diluted, purified, concentrated, filtered, dissolved, suspended or otherwise manipulated prior to use in the assay. Preferably, a sample containing particulate matter is diluted, filtered, or both diluted and filtered prior to use.

The preferred biological sample is a biological body fluid sample that is easily and routinely available, such as blood serum or plasma, saliva, cerebrospinal fluid and similar body fluids. The sample size for the biological fluid sample is preferably between approximately 0.25 μ l and 1 ml.

For example, once the sample is obtained, viral RNA is extracted from the sample by methods known in the art, such as those taught by Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, New York, 1989), or from commercial kits, such as the QIAamp viral RNA extraction kit (Quiagen, Valencia, CA). The viral RNA is then used as a template to synthesize cDNA by using a polymerase, such as reverse transcriptase, or other replication methods known in the art.

The synthesized strand is amplified by any of the amplification protocols known in the art now or in the future, including but not limited to PCR, ligation amplification reaction (LAR), ligase-based amplification system (LAS), the self-sustained sequence replication (3SR) system, the transcription-based amplification system (TAS), and the Q β replicase amplification method. The preferred amplification method is PCR.

For amplification by PCR, the conditions for amplification can include 30-40 cycles (preferably 35 cycles) of heating the synthesized DNA and primer pair at 93 to 97°C (preferably 95°C) for 30 to 90 seconds (preferably 30 seconds), at 45 to 57°C (preferably 50-55°C) for 30 to 90 seconds (preferably 30 seconds), and at 70 to 74°C (preferably 72°C) for 30 to 90 seconds (preferably one minute).

After amplification, or nested amplification, the amplified product is confirmed by methods known to those skilled in the art, such as electrophoresis, preferably using ethidium bromide staining and Southern blot hybridization methods. Alternatively, one or more of the nucleotides that are incorporated into the amplified product are labeled with a detectable label so that the amplified product itself is detectable. As a further alternative, the amplified product is detected by incubation with a detectable probe that selectively anneals to the amplified product and then detecting or measuring the concentration of the detectable probe. Detection of the detectable probe indicates the presence of HIV-1 RNA and/or DNA in the biological sample under

investigation. If an HIV-1 group M, N or O RNA or DNA exists in the biological sample, the amplification product will be detected, preferably with a detection accuracy of greater than 96%. Additional sensitivity is achieved by subsequently employing additional amplification steps, such as amplification using other primers, particularly *pol* primers, to achieve as much as 100% detection of HIV-1 in an HIV-1 positive sample.

As described above, the assays particularly useful for the detection of group M, N and O RNA and/or DNA in a sample when the probes or primers for group M, N and O RNA or DNA (most preferably SEQ ID NOS: 1-4) are combined with the probes or primers specific for groups M, N and O and SIV SIVcpz RNA or DNA (most preferably SEQ ID NOS: 1-9).

Compositions and methods for labeling and detecting nucleotides or nucleic acid detection probes are well known to those skilled in the art. For example, the nucleotides or nucleotide triphosphates (NTPs) are labeled with biotin, which binds to streptavidin; digoxigenin, which binds to anti-digoxigenin; or 2,4-dinitrophenol (DNP), which binds to anti-DNP. The streptavidin or antibody molecule is conjugated to a detectable molecule, such as an enzyme that is then reacted with its substrate to produce a detectable reaction, such as a color change. Radioactivity, fluorogens, or chemiluminescent labels can also be used as labels. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycoerythrin, phycoerythrin, rhodamine, Texas Red or other proprietary fluorogens. The fluorogens are generally attached by chemical modification and bind to a fluorogen-specific antibody, such as anti-fluorescein. It will be understood by those skilled in the art that the nucleotides or probes can also be labeled by incorporation of a modified base containing any chemical group recognizable by specific antibodies. Other labels and methods of labeling nucleotides are well known to those skilled in the art. A review of nucleic acid labels can be found in the article by Landegren, *et al.*, "DNA Diagnostics-Molecular Techniques and

Automation", *Science*, 242:229-237 (1988). Most preferably, the nucleotide UTP is biotinylated.

If the biological sample is a patient sample, then the detection of HIV-1 nucleic acids in the sample using the oligonucleotide primers described herein indicates that the patient is infected with the virus. Therefore, the primers are useful in an assay for the diagnosis of HIV-1 infection.

Alternatively, if the biological sample is an individual blood sample or pooled blood sample from blood or a blood product that will be administered to a patient, such as a blood transfusion or blood clotting factor recipient, then the detection of HIV-1 nucleic acids in the sample using the oligonucleotide primers described herein indicates that the blood or blood product is contaminated with HIV-1 and should be discarded or treated to inactivate or remove the virus, thereby preventing transmission of the virus to the blood or blood product recipient. In addition, biological samples to be analyzed or processed by health care workers can be screened for HIV-1 contamination so that the individual handling the sample will exercise caution to prevent self-contamination and possible infection.

Use of the detection assay described herein will impact the safety of the blood supply by reducing blood transfusion associated HIV infections within the "window period." First, given the high sensitivity of detection, the assay will detect the presence of viral RNA early in the course of the infection. Second, testing of blood donations will not be dependent on the geographic origin of the donor. The very high sensitivity of the assay for any group M, N or O infection makes it an ideal candidate for genomic screening of the blood supplies maintained by all nations of the world.

In addition to being highly sensitive for detection of group M, group N and group O HIV-1, the assays are highly specific for HIV-1 and do not erroneously amplify or detect HIV-2 or SIV (other than chimpanzee) nucleic acid molecules. Further, the assay is highly accurate in that false positive results are minimized or entirely absent.

Viral Load Assay

5 Viral load determinations are commonly used to monitor
the progression of HIV-1 infection and response to antiviral
treatment in a patient who has been diagnosed as HIV-positive.
An increase in viral load is an indication that the virus is not
responsive to the therapy being administered, possibly indicating
the onset of drug resistance. In addition, viral load
10 determinations are used in laboratory research to assess HIV
proliferation under certain conditions. For example, viral load
determinations are made in the presence of an experimental
antiviral therapy or drug to screen for new treatment regimens.
Viral load determination may also be useful in determining the
mechanisms of HIV replication so that additional therapies may
15 be designed. These determinations provide a quantitative
assessment of the concentration of virus in a sample.

 The probes, primers and assays described above can be
adapted for determining viral loads in a biological sample using
the techniques of hybridization, replication, amplification and
20 detection described above. The above-described assays are
simultaneously conducted with assays using known or spiked
quantities of virus in a control biological sample to produce a
standard curve. By comparing the experimental assay results
with the standard curve, the quantity of virus in the sample is
25 determined. This quantity is defined mathematically as the viral
load.

 The measurement of plasma HIV-1 RNA has become an
important tool in the clinical management of HIV-1 infected
persons, and has clear advantages over other virological assays.
30 In contrast to HIV-1 p24 antigen levels, plasma viremia is
measurable in a vast majority of HIV-infected patients at various
stages of disease. In contrast to HIV-1 proviral DNA levels in
peripheral mononuclear cells, HIV-1 RNA levels in plasma
change dynamically in response to successful therapy.
35 Therefore, HIV-1 RNA levels in plasma are the most effective
single predictor of clinical outcome. However, a disadvantage of

currently available commercial viral load assays is that they are unable to detect certain group M non-B subtypes and many group O viruses. In contrast, the group M, N and O primers described herein allow amplification of all subtypes of group M as well as group O viruses. Thus, currently available assays, such as the AMPLICOR™, Nuclisense™ and Quantiplex™ nucleic acid amplification methods, can be adapted, by use of the primers described herein, to accurately quantitate virtually any HIV-1 RNA or DNA targets from any specimen regardless of geographic origin or viral genotype, and thereby provide a rapid, efficient and accurate test for monitoring response to therapy.

HIV-1 Detection Kits

Kits for detecting HIV-1 groups M, N and O virus in a biological sample contain one or more of the oligonucleotide probes or primers described herein and reagents for the detection of viral RNA or DNA to which the probes or primers have hybridized, either by detection of a hybridized probe or detection of an amplified product. The probes, primers and reagents are provided in separate containers or are combined in a single container depending on the assay employed and the stability of the components when combined.

The kit may optionally contain additional primers, such as primers composing a nested primer pair, a hybridization probe for detection of the amplified DNA product, an apparatus for conducting the assay, an apparatus for assay detection, one or more containers for obtaining and storing the sample prior to and during analysis, and suitable buffers, cations, nucleotides and other reagents to facilitate nucleic acid isolation, extraction, hybridization, synthesis, amplification and detection. In addition, the kit may contain reagents for confirming amplification, such as ethidium bromide, and reagents for the preparation of a standard curve, such as known concentrations or aliquots of the target nucleic acid molecule to be amplified by the primers.

The kits may also contain probes or primers specific for the detection or amplification of group N HIV-1. Alternatively, separate kits may be available for group N detection.

The invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.

Example 1

Determination of HIV-1 Assay Sensitivity and Specificity

Blood plasma samples obtained from HIV-positive patients were tested using gp41 HIV-1 primers (SEQ ID NOS:1-5) to amplify and detect HIV-1 nucleic acids.

Primers for Detection of HIV-1 Groups M and O

The following oligonucleotides, referred to herein as consensus primers or gp41 primers, were synthesized at the Biotechnology Core Facility, Centers for Diseases Control and Prevention (Atlanta, GA).

For reverse transcription and primary PCR, the following primers were used:

GP40F1(forward) (SEQ ID NO:1)

5' TCTTAGGAGCAGCAGGAAGCACTATGGG

GP41R1(reverse) (SEQ ID NO:2)

5' AACGACAAAGGTGAGTATCCCTGCCTAA

For nested PCR, the following primers were used:

GP46F2(forward) (SEQ ID NO:3)

5' ACAATTATTGTCTGGTATAGTGCAACAGCA

GP47R2(reverse) (SEQ ID NO:4)

5' TTAAACCTATCAAGCCTCCTACTATCATTA

GP48R2(reverse) (SEQ ID NO:5)

5' TCCTACTATCTTAATGAATATTTTATATA 3'

5 The sensitivity of the assay for HIV-1 group M specimens (viral isolates) was examined using viral DNA. Viral isolates representing various group O and group N HIV-1 subtypes, HIV-2 isolates and SIV isolates were expanded as described by Xiao *et al.*, *Virol.* 240:83-92 (1998) and Owen *et al.*, *J. Virol.* 72:5425-5432 (1998). The SIV isolates were either obtained from the AIDS Reagent and Reference Program (Rockville, MD) or were primary isolates obtained from naturally infected monkeys. Viral RNA was extracted from the culture supernatants and tested for initial sensitivity and specificity of the primers.

15 Full-length cloned sequences of HIV-1 subtype A-H (Gao *et al.*, *J. Virol.* 72:5680-5688 (1998)) were employed to determine the sensitivity of the primers. Serial dilutions with known copy numbers of full length genomic clones representing subtypes A (92UG037.1), B (YU2, SG3), C (92BR025.8), D (94UG114.1), A/E (90CF402.8), F (93BR020.1), A/G (92NG003.1) and H (90CF056.1) demonstrated that most subtypes were detectable in an agarose gel assay at one to five copies/PCR reaction. Thus, the gp41 group M and O primer set (GP46F2 and GP47R2, referred to herein as gp46/47) as well as the group M, N, O and SIVcpz primer set (GP46F2 and GP48R2, referred to herein as gp46/48) were highly sensitive for detection of viral DNA regardless of viral genotypes.

25 Further analysis also revealed that the primers (gp46/47) were specific for HIV-1 only, since the culture supernatants from primary HIV-2 isolates (GB87, IC77618, IC310319, IC310072, SLRHC14), SIV isolates (MAC239, SMM 1, SIV-ST, M156, SM55, SM74) and an SIV chimpanzee isolate (SIVcpz) could not be amplified by gp46/47. However, the gp46/48 primers amplify three of the four known chimpanzee viruses known to date.

35 The results are shown below in Table 1.

Table 1

Sensitivity of gp46/47 and gp46/48 primers in detecting HIV-1 clones and proviral DNAs of HIV-1 Groups M, O, and N and SIVcpz

HIV/SIV groups	Copies/ PCR	Group M/O gp46/47	Group M/N/O/ SIVcpz gp46/48
Group M			
Subtype A			
92UG037.1	5	+	+
	1	+	+
Subtype B			
YU2	5	+	+
	1	-	-
SG3	5	+	+
	1	+	+
Subtype C			
92BR025.8	5	+	+
	1	+	+
Subtype D			
94UG114.1	5	+	+
	1	+	+
Subtype A/E			
90CF402.8	5	+	+
	1	-	-
Subtype F			
93BR020.1	5	+	+
	1	-	-
Subtype A/G			
92NG003.1	5	-	-
	1	+	+
Subtype H			
90CF056.1	5	+	+
	1	+	+

1996-1997 1997-1998 1998-1999 1999-2000 2000-2001 2001-2002 2002-2003 2003-2004 2004-2005 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010 2010-2011 2011-2012 2012-2013 2013-2014 2014-2015 2015-2016 2016-2017 2017-2018 2018-2019 2019-2020 2020-2021 2021-2022 2022-2023 2023-2024 2024-2025 2025-2026 2026-2027 2027-2028 2028-2029 2029-2030 2030-2031 2031-2032 2032-2033 2033-2034 2034-2035 2035-2036 2036-2037 2037-2038 2038-2039 2039-2040 2040-2041 2041-2042 2042-2043 2043-2044 2044-2045 2045-2046 2046-2047 2047-2048 2048-2049 2049-2050 2050-2051 2051-2052 2052-2053 2053-2054 2054-2055 2055-2056 2056-2057 2057-2058 2058-2059 2059-2060 2060-2061 2061-2062 2062-2063 2063-2064 2064-2065 2065-2066 2066-2067 2067-2068 2068-2069 2069-2070 2070-2071 2071-2072 2072-2073 2073-2074 2074-2075 2075-2076 2076-2077 2077-2078 2078-2079 2079-2080 2080-2081 2081-2082 2082-2083 2083-2084 2084-2085 2085-2086 2086-2087 2087-2088 2088-2089 2089-2090 2090-2091 2091-2092 2092-2093 2093-2094 2094-2095 2095-2096 2096-2097 2097-2098 2098-2099 2099-2100 2100-2101 2101-2102 2102-2103 2103-2104 2104-2105 2105-2106 2106-2107 2107-2108 2108-2109 2109-2110 2110-2111 2111-2112 2112-2113 2113-2114 2114-2115 2115-2116 2116-2117 2117-2118 2118-2119 2119-2120 2120-2121 2121-2122 2122-2123 2123-2124 2124-2125 2125-2126 2126-2127 2127-2128 2128-2129 2129-2130 2130-2131 2131-2132 2132-2133 2133-2134 2134-2135 2135-2136 2136-2137 2137-2138 2138-2139 2139-2140 2140-2141 2141-2142 2142-2143 2143-2144 2144-2145 2145-2146 2146-2147 2147-2148 2148-2149 2149-2150 2150-2151 2151-2152 2152-2153 2153-2154 2154-2155 2155-2156 2156-2157 2157-2158 2158-2159 2159-2160 2160-2161 2161-2162 2162-2163 2163-2164 2164-2165 2165-2166 2166-2167 2167-2168 2168-2169 2169-2170 2170-2171 2171-2172 2172-2173 2173-2174 2174-2175 2175-2176 2176-2177 2177-2178 2178-2179 2179-2180 2180-2181 2181-2182 2182-2183 2183-2184 2184-2185 2185-2186 2186-2187 2187-2188 2188-2189 2189-2190 2190-2191 2191-2192 2192-2193 2193-2194 2194-2195 2195-2196 2196-2197 2197-2198 2198-2199 2199-2200 2200-2201 2201-2202 2202-2203 2203-2204 2204-2205 2205-2206 2206-2207 2207-2208 2208-2209 2209-2210 2210-2211 2211-2212 2212-2213 2213-2214 2214-2215 2215-2216 2216-2217 2217-2218 2218-2219 2219-2220 2220-2221 2221-2222 2222-2223 2223-2224 2224-2225 2225-2226 2226-2227 2227-2228 2228-2229 2229-2230 2230-2231 2231-2232 2232-2233 2233-2234 2234-2235 2235-2236 2236-2237 2237-2238 2238-2239 2239-2240 2240-2241 2241-2242 2242-2243 2243-2244 2244-2245 2245-2246 2246-2247 2247-2248 2248-2249 2249-2250 2250-2251 2251-2252 2252-2253 2253-2254 2254-2255 2255-2256 2256-2257 2257-2258 2258-2259 2259-2260 2260-2261 2261-2262 2262-2263 2263-2264 2264-2265 2265-2266 2266-2267 2267-2268 2268-2269 2269-2270 2270-2271 2271-2272 2272-2273 2273-2274 2274-2275 2275-2276 2276-2277 2277-2278 2278-2279 2279-2280 2280-2281 2281-2282 2282-2283 2283-2284 2284-2285 2285-2286 2286-2287 22	
---	--

Table 1 (continued)

Group O

11516 (MD)	+	+
191265(CA)	+	+

Group N

YBF30	+	+
-------	---	---

SIVcpz

SIVcpzUS	+	+
SIVcpzGAB1	-	+
SIVcpzGAB2	-	-
SIVcpzANT	-	+

Example 2

Detection of HIV-1 Group M and O RNA
in International HIV-positive Samples

5 Blood plasma samples obtained from various HIV-positive patients were tested using the gp41 HIV-1 primers to amplify and detect HIV-1 nucleic acids as described in Example 1 above.

Sample Selection and RNA extraction

10 Plasma samples to be tested using the primers described above were obtained from various ongoing HIV studies around the world. All samples had previously been shown to have antibodies to HIV-1. These included serum and/or plasma specimens from Uganda (n=54), Thailand (n=43), Cameroon (n=40), Ivory Coast (n=29), Argentina (n=27), Brazil (n=23),
15 United States (n=16), Ghana (n=8), Mexico (n=8), China (n=6), Lebanon (n=5), Zimbabwe (n=4), S. Africa (n=4), Spain (n=4), India (n=3), and miscellaneous (n=7). The specificity of the assay was tested against specimens from HIV-2 infected individuals
20 from the Ivory Coast (n=19) and Ghana (n=2), as well as HIV seronegative donors from the United States (n=41). HIV-1 early

seroconversion panels (five panels) were obtained from Boston Biomedica Inc. (Boston, MA).

Plasma viral RNA was extracted from each sample using a QIAamp™ viral RNA extraction kit according to the manufacturer's protocol (Quiagen, Valencia, CA). 200 µL of plasma were mixed with 800 µL of lysis buffer AVL. After a 10 minute incubation at room temperature, 800 µL of 100% ethanol was added to the lysate. The mixture was filtered through a column by centrifugation. After washing with buffer AW, the RNA was eluted from the column by adding 50 µL of RNase-free water. For negative controls, normal human plasma RNA was extracted simultaneously.

Reverse transcription, PCR and nested PCR

Viral RNA (3-10 µL) from each sample was used to synthesize cDNA using 20 pM of the primer GP41R1 (SEQ ID NO:2) and a GeneAmp™ RNA PCR kit with 5mM MgCl₂ following the manufacturer's protocol (Perkin-Elmer Cetus, Norwalk, CT).

The 20 µL cDNA reaction was added to a PCR mixture containing 50 pM of GP40F1 (SEQ ID NO:1) and 30 pM of GP41R1 (SEQ ID NO:2), 1 X GeneAmp™ PCR buffer II (Perkin-Elmer Cetus, Norwalk, CT), 1-25 mM MgCl₂, 2.5 U of AmpliTaq™ DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT), and the mixture was brought to a final volume of 100 µL with sterile distilled water. After initial denaturation at 94°C for two minutes, 35 cycles of PCR were performed in the GeneAmp™ 9600 nucleic acid amplifier (Perkin-Elmer Cetus, Norwalk, CT). Each cycle consisted of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, and extension at 72°C for 60 seconds, with a final extension at 72°C for five minutes. For nested PCR, 5 µL of the primary PCR product was added to a 100 µL PCR reaction mixture containing the same reagents as primary PCR except that the primers were replaced by 25 pM of each GP46F2 (SEQ ID NO:3) and

GP47R2 (SEQ ID NO:4). The PCR reactions were subjected to 35 cycles using the same conditions as the primary PCR.

After PCR, the nested PCR products of expected size (460 bp) were detected by electrophoresis in 1.5% agarose gels along with a 100 bp ladder (Gibco, Grand Island, NY) and visualized under ultraviolet light (UV) by ethidium bromide staining. Sequence analysis confirmed gp41 regions. The same procedure also successfully amplified and detected viral DNA extracted from patient peripheral blood mononuclear cells (PBMCs).

Example 3

Determination of gp41 Amplification Assay Sensitivity in Clinical Specimens Including Group M and Group O

The sensitivity of plasma RNA detection using the gp41 assay, as described in Example 1, was examined using a panel of plasma for which viral subtypes were already established by phylogenetic analysis of the envelope region (C2V3 or gp41). RT-PCR analysis of 68 specimens having HIV-1 subtype A infections, obtained from diverse geographic locations, revealed that the nucleic acid molecules from 67 of the specimens (98.5%) could be amplified using the gp41 amplification assay, as shown in Table 2 below.

Table 2

Detection of plasma RNA from phylogenetically distinct HIV-1 group M and group O specimens using generic primers gp46/47

HIV type	Country of origin	Number tested	Number positive	% positive
1. Group M:				
Subtype A				
	Ivory Coast	20	19	95
	Uganda	24 *	24	100
	Cameroon	15	15	100
	Ghana/Lebanon	6/3	9	100
	Total	68	67	98.5

Table 2 (continued)

	United States	11	11	100
	Mexico	8	8	100
	Brazil	19	17	90
	China	6	6	100
	Thailand	20	20	100
	Misc.	7	7	100
	Total	71	69	97.2
Subtype C				
	Zimbabwe	4	4	100
	S. Africa	4*	4	100
	India	3	3	100
	Uganda	4	4	100
	United States	3	3	100
	Lebanon	1	1	100
	Total	19	19	100
Subtype D				
	Uganda	26	26	100
	Lebanon	1	1	100
	Total	27	27	100
Subtype E				
	Thailand	23	23	100
Subtype F				
	Argentina	27*	27	100
	Brazil	4	4	100
	Japan	2	2	100
	Total	33	33	100
Subtype G				
	Ghana/Lebanon	2/1	3	100
	Ivory Coast	9	9	100
	Total	12	12	100
2. Group O				
	Cameroon	25	25	100
	Spain	5	5	100
	United States	2	2	100
	Total	32	32	100
3. HIV-2				
	Ivory Coast	19	0**	0
	Ghana	2	0	0
	Total	21	0	0
4. HIV negative				
	United States	41	0	0

* Represents one specimen each of potential recombinant with discordance in *env* and *prt* subtype: specimen from Uganda represents A *env*/ B-Dprt, specimen from South Africa is C *env*/Bprt, and specimen from Argentina is F *env*/Bprt.

** Three specimens include persons with HIV-1 and HIV-2 dual infections.

107090 "15506860

Likewise, 69 of 71 (97%) subtype B, 19 of 19 (100%) subtype C, 27 of 27 (100%) subtype D, 23 of 23 (100%) subtype E, 33 of 33 (100%) of subtype F, and 12 of 12 (100%) subtype G gave a positive reaction using the gp41 amplification assay. Overall sensitivity of the gp41 amplification assay for plasma detection of HIV-1 group M subtypes was 98.8% (250 of 253). The three specimens testing negative by the GP46F2 (SEQ ID NO:3) and GP47R2 (SEQ ID NO:4) primer set were amplified using the GP46F2 and GP48R2 (SEQ ID NO:5) primer set, suggesting that the sequence variation on the GP47R2 primer may be the reason for lack of gp41 amplification.

The gp41 amplification assay was also able to amplify plasma viral RNA from individuals infected with HIV-1 group O viruses. Of the 32 group O plasma representing specimens from Cameroon, Spain, Belgium and US, 32 (100%) were amplifiable with the gp41 amplification assay.

The gp41 amplification assay is highly specific for HIV-1 only, because neither plasma from HIV-2 (n=21) nor uninfected controls (n=41) were amplified in the assay as shown in Table 2. The three specimens that tested positive using the gp41 group M and O primers in the HIV-2 infected group were from persons dually infected with HIV-1 and HIV-2.

Additional testing of gp41 (46/48) was performed using RNA from clinical specimens. The results are shown in Table 3 below.

Table 3

Detection of plasma RNA from phylogenetically distinct HIV-1 group M, N, and O specimens using generic primers gp46/48

1. Group M				
Subtype A	Ghana	14	14	100
	Ivory Coast	26	26	100
	Uganda	20	20	100
	<u>Misc.</u>	<u>4</u>	<u>4</u>	<u>100</u>
	Total	64	64	100
Subtype B				
	Brazil	19	19	100
	Thailand	20	20	100
	<u>Misc.</u>	<u>16</u>	<u>15</u>	<u>93.8</u>
	Total	55	54	98.2
Subtype C				
	Uganda	5	5	100
	Zimbabwe	13	13	100
	<u>Misc.</u>	<u>3</u>	<u>3</u>	<u>100</u>
	Total	21	21	100
Subtype D				
	Uganda	31	31	100
	<u>Lebanon</u>	<u>1</u>	<u>1</u>	<u>100</u>
	Total	32	32	100
Subtype E				
	Thailand	23	23	100
Subtype F				
	Argentina	26	25	96.2
	Brazil	4	4	100
	<u>Japan</u>	<u>2</u>	<u>2</u>	<u>100</u>
	Total	32	31	96.9
Subtype G				
	Ivory Coast	10	9	90.0
	Ghana	5	5	100
	<u>Lebanon</u>	<u>1</u>	<u>1</u>	<u>100</u>
	Total	16	15	93.8
2. Group O				
	Cameroon	26	26	100
	Spain	4	4	100
	<u>United States</u>	<u>2</u>	<u>2</u>	<u>100</u>
	Total	32	32	100
3. Group N				
	Cameroon (DNA)	1	1	100
4. HIV-negative				
		41	0	0

T01050" T5506B50

Example 4*Determination of HIV-1 Assay Sensitivity
for Group M, Subtype B*5 Assay Detection Sensitivity

10 HIV-1 stock at 1000, 100, 50, 25, 10 and 1 copies/ml was spiked in normal human plasma to test the sensitivity of detection using the primer sets and methods of the gp41 HIV-1 amplification assay described in Example 1. Ten microliters of viral RNA in duplicate from each sample was used to synthesize cDNA. The total cDNA reaction was then used for primary PCR. Following primary PCR, 5 μ L of the primary PCR product were used for the nested PCR. Amplification was confirmed by electrophoresis and ethidium bromide staining.

15 *In vitro* spiking of HIV-1 subtype B with known copies in the plasma prior to RNA extraction and RT-PCR established that the gp41 group M and O primers were able to reliably detect as few as 25 copies/ml of HIV-1 RNA in an agarose gel assay.

20 The sensitivity of the assay for early detection of plasma viremia in seroconversion cases was examined. Analysis of five seroconverters from the United States (all subtype B) revealed that in all cases, RT-PCR detection preceded both HIV-1 antibody and p24 antigen detection. The early detection levels were comparable to other RNA based detection assays.
25 However, in one case the gp41 group M, N and O assay was more sensitive for early detection of plasma viremia during the "window period." The gp46/48 primers gave the same results as the gp46/47 primers.

30 **Example 5***Comparison of gp41 HIV-1 Amplification Assay
with Commercially Available Viral Load Assays*

35 The assay described above in Example 1, referred to herein as the gp41 assay, was used to detect plasma viremia from specimens that had previously been shown to be low or

undetectable by commercial RNA load assays. The commercially available assays for quantitation of HIV-1 RNA in plasma were the AMPLICOR™ HIV-1 Monitor kit, which is based on PCR (Roche Molecular Systems, Raritan, NJ); the Nuclisense™ HIV-1 QT assay (Organon Technika, Durham, NC) which is based on an isothermal nucleic acid sequence-based amplification (OTC); and the Quantiplex™ HIV RNA assay, which uses the branched DNA (bDNA) signal amplification techniques (Chiron Corp., Emoryville, CA) (Cavert, *AIDS* 12 (Suppl. A):S27 (1998)). These included 21 specimens, representing group M subtypes A-G, and group O, in which at least one of the three commercial assays were unable to detect the virus. Data is shown below in Table 4.

Subtype was ascribed based on a phylogenetic analysis of the *env* region. In some cases, the protease region was also sequenced to identify potential dual infections or recombinants. Specimen numbers 301-14, 301-27, 301-39, and 301-47 represented dual infections with multiple subtypes or potential recombinants of two different genotypes. The abbreviation "BLD" in Table 4 means that the samples were below detection. The abbreviation "ND" indicates that the assay was not done for that sample. The detection limit of each assay was 500 copies/ml for Chiron and 400 copies/ml for OTC and Roche.

Table 4
Comparative analysis of viral RNA detection in plasma using gp41
amplification assay vs. commercial viral load assays

Specimen	Country	Subtype	Viral load assays			gp41 assay
			<i>env/prt</i>	Chiron	OTC	
301-06	Ghana	A	4x10 ³	5x10 ³	BLD	+
301-07	Ghana	A	5x10 ³	2x10 ³	BLD	+
301-12	Ghana	A	6x10 ⁴	3x10 ⁴	BLD	+
301-21	Uganda	A/A	7x10 ²	BLD	BLD	+
301-24	Uganda	A	BLD	9x10 ²	6x10 ²	+
301-27	Uganda	A/BD	BLD	BLD	BLD	+
TIA175	Ivory Coast	A	ND	BLD*	BLD*	+
301-14	South Africa	C/B	4x10 ³	BLD	7x10 ²	+
301-16	South Africa	C	3x10 ³	9x10 ²	BLD	+
301-29	Zimbabwe	C	>8x10 ⁵	1x10 ³	BLD	+
301-44	India	C	4x10 ³	BLD	3x10 ³	+
301-23	Uganda	D	BLD	BLD	BLD	+
301-26	Uganda	D/D	2x10 ³	BLD	5x10 ²	+
301-39	Zimbabwe	E/A	4x10 ³	BLD	BLD	+
301-40	Thailand	E	2x10 ³	BLD	BLD	+
301-47	Argentina	F/B	BLD	BLD	BLD	+
301-03	Ghana	G	1x10 ³	BLD	BLD	+
301-08	Ghana	G	1x10 ³	7x10 ²	BLD	+
DAA3671	Ivory Coast	G	ND	BLD*	BLD*	+
DAA3760	Ivory Coast	G	ND	BLD*	BLD*	+
301-01	Cameroon	O	BLD	BLD	BLD	+

*Represents specimens which were still negative by ultrasensitive version of OTC and Roche (both with lower limit of detection of 50 copies/ml).

In addition, three specimens which were negative even by the ultrasensitive Roche and OTC assays were positive using the gp41 assay. Thus, all 21 (100%) of the 21 specimens, including one group O specimen, demonstrated a positive amplifiable signal by the consensus gp41 amplification assay. Taken together, the data demonstrate that the primers of the gp41 amplification assay provide better sensitivities for plasma viral RNA detection for all known subtypes of HIV-1 group M and group O viruses than currently available commercial assays.

Example 6*Enhanced Sensitivity and Specificity with Detection of gp41 and Integrase Proteins*

Blood plasma samples obtained from HIV-positive patients were tested using the gp41 HIV-1 primers described herein (SEQ ID NOS:1-9) to amplify and detect HIV-1 nucleic acids as described above. In addition, plasma samples were also obtained from 41 HIV-1-seronegative U.S. blood donors and 16 HIV-2-positive West Africans. Plasma samples from two captive chimpanzees (Noah and Niko) infected with SIVcpzANT were also tested as well as uncultured spleen and plasma from another captive chimpanzee (Marilyn) infected with SIVcpzUS.

Primers and Probes

Nested sets of PCR primers were designed based on highly conserved HIV-1 and SIVcpz regions in integrase and gp41. The outer primers of gp41 are the same as described in Examples 1-5 above and correspond to SEQ ID NOS:1-3, and 5. The outer primers for integrase are INTFI (forward; SEQ ID NO. 6), and INTR1 (reverse; SEQ ID NO. 7); the inner primers are INTF2 (forward; SEQ ID NO.8) and INTR2 (reverse; SEQ ID NO.9). The protocols for RNA extraction and conditions for RT-PCR and PCR are as described above, except that an annealing temperature of 55°C was used for the nested PCR with the integrase primer set.

Results

Both gp41 and integrase primer sets reliably amplified as few as 10 copies of near full length clones of HIV-1 group M subtypes A-H. In most instances, 1 to 5 copies per PCR reaction were also detectable (FIG. 1, panels A and C, Table 5). Similarly, gp41 and integrase primer pairs amplified viral RNAs from culture supernatants of HIV-1 group O isolates (BCF1, BCF2, BCF3, and 3012), as well as cultured PBMC DNA from HIV-1 group N (YBF30) (FIG. 1, panels B and D, Table 5). Most

importantly, both primer pairs amplified simian immunodeficiency viruses derived from two chimpanzee subspecies, *i.e.*, SIVcpzGAB1, SIVcpzUS) and SIVcpzANT (FIG. 1B and D, Table 5). However, none of the 4 SIVsm isolates were amplified with either primer set (Table 5). Thus, in contrast to the gp41 primer set described above, for groups M and O, *i.e.*, SEQ. ID NOS.: 1-4, which does not amplify SIVcpz, the primer sets for gp41, *i.e.* SEQ ID NOS.: 1-3, 5 combined with those for integrase, SEQ. ID NOS.: 6-9 can amplify members of all known HIV-1 and SIVcpz lineages (Table 5).

Amplification of HIV-1 and SIVcpz viral RNA from plasma

Also examined was the amplification efficiency of gp41 and integrase primers in detecting plasma viremia from 216 HIV-1 group M (subtypes A-H) plasma specimens, and 17 HIV-1 group O specimens (Table 6). Of the 216 group M specimens, 214 (99%) were amplified by gp41 primers and 215 (99.5%) by integrase primers; one subtype B specimen was missed by both primers, whereas one subtype G was missed only by gp41 (Table 6). In addition, all 17 HIV-1 group O plasma specimens were amplified by both gp41 and integrase primers (Table 6). No plasma specimens from persons infected with group N viruses were available. Finally, both primer sets yielded positive amplifications from chimpanzee plasma samples. SIVcpzUS was amplified from the plasma of Marilyn and SIVcpzANT from the plasma of Noah and Niko (Table 6). By contrast, plasma specimens from the HIV-2-infected patients (n=16) and the HIV-1 negative blood donors (n=41) gave no amplifications (Table 6). Spiking of normal human plasma with known copy numbers of HIV-1 subtype B virus established that the gp41 primers can reliably detect as few as 25 copies/ml of HIV-1 RNA (data not shown).

Phylogenetic classification

Phylogenetic analysis of primate lentiviral sequences provides the basis for their classification into groups and

subtypes for HIV-1 and into major lineages for SIVcpz. An examination was made as to whether the sequences derived from the integrase and gp41 amplification products were of sufficient length to provide reliable phylogenetic information. Selected PCR products from 143 HIV-1 group M (A=22, B=34, C=19, D=24, E=22, F=9, G=12, and H=1), group O (n=17), and group N (YBF30) specimens and SIVcpz specimens (US, GAB1, ANTnoah and ANTniko) were sequenced and used for phylogenetic tree construction. Figure 2A depicts the relationships of sequences derived from the amplified integrase region. The topology shows an overall branching order very similar to the orders previously reported for full-length *pol* sequences. Newly amplified group M and O viruses (shown in bold) are readily identified as such, since they cluster with previously characterized reference sequences. YBF30, the single representative of HIV-1 group N, clusters as expected between groups M and O. Finally, the relative positions of the PCR-derived SIVcpzUS, SIVcpzGAB1, and SIVcpzANT integrase fragments are consistent with those previously identified for their full length sequences. The only shortcoming of the amplified IN region is that it is not suitable (because of its length and conservation) for more detailed subtype classification of HIV-1 group M viruses. However, such classification is possible for sequences derived from the gp41 amplification products. As shown in FIGs. 2A and B, a phylogenetic tree constructed from the subgenomic gp41 sequences yields an overall topology that is very similar to that of a full length *env* tree. Thus, 28 newly sequenced group M viruses (depicted in bold) are readily classified into group M subtypes A (4), B(4), C (4), D (5), E (3), F (3), G (4), and H (1). Finally, analysis of gp41 sequences can also be used to classify new SIVcpz strains. Sequences amplified from the plasma of a chimpanzee (Niko) experimentally infected with SIVcpzANT cluster very closely with sequences derived from the plasma of the chimpanzee (Noah) naturally infected with this isolate. Taken together, a PCR-based approach that utilizes both integrase and gp41 primers should be useful in

assays to definitively type newly identified HIV-1 as well as SIVcpz strains.

Table 5

Cross-reactivity of gp41 and integrase primer sets

	HIV/SIV	NAME	MATERIAL	gp41 region		Integrase	
				gpM/O*	gpM-Z*	intM-Z*	
10							
	HIV-1						
	Group M						
	Subtype A	92UG027.1	clone	1	1	1	
15	Subtype B	YU2	clone	5	5	1	
		SG3	clone	1	1	1	
	Subtype C	92BR025.8	clone	1	1	1	
20	Subtype D	94UG114.1	clone	1	1	1	
	Subtype A/E	90CF402.8	clone	5	5	5	
	Subtype F	93BR020.1	clone	5	5	1	
25	Subtype A/G	92NG003.1	clone	1	1	10	
	Subtype H	90CF056.1	clone	1	1	1	
30	Group O	BCF01	culture sup	+	+	+	
		BCF02	culture sup	+	+	+	
		BCF03	culture sup	+	+	+	
		3012	culture sup	+	+	+	
35	Group N	YBF30	cultured PBMC DNA	+	+	+	
		SIVcpz	SIVcpzUS	spleen	-	+	+
		SIVspzBAB1	culture sup	-	+	+	
		SIVcpzANT	cultured PBL	-	+	+	
40	SIVsm	SIVsm3	cultured PBL	-	-	-	
		SIVsm21	cultured PBL	-	-	-	
		SIVsm55	cultured PBL	-	-	-	
		SIVsm156	cultured PBL	-	-	-	

* The amplification using the primer sets is shown as number of copies per PCR reaction amplified for HIV-1 group M reference clones, and as positive (+) or negative (-) amplification for HIV-1 group O and group N, and SIV isolates.

Table 6

Amplification of HIV-1 (groups M and O) and SIV cpz viral RNA in human and chimpanzee plasmas using gp41 and integrase primer sets

5	HIV Type	Country of origin	#.tested	RT-PCR amplification of plasma	
				gp41	integrase
10	HIV-1 Group M				
	Subtype A				
		Ghana	11	11	11
		Ivory Coast	25	25	25
		Uganda	21	21	21
15		Misc	4	4	4
	Total		61	61	61
	Subtype B				
		Brazil	17	16	16
20		Thailand	17	17	17
		Misc	13	13	13
	Total		47	46	46
	Subtype C				
25		Uganda	4	4	4
		Zimbabwe	8	8	8
		Mozambique	5	5	5
		India	2	2	2
	Total		19	19	19
30	Subtype D				
		Uganda	28	28	28
		Lebanon	1	1	1
	Total		29	29	29
35	Subtype E				
		Thailand	22	22	22
	Subtype F				
40		Argentina	23	23	23
		Japan	2	2	2
	Total		25	25	25
	Subtype G				
45		Ivory Coast	9	8	9
		Ghana	3	3	3
	Total		12	11	12
	Subtype H				
50		Zaire	1	1	1
	HIV-1 Group O				
		Cameroon	8	8	8
		Spain	7	7	7
55		US	2	2	2
	Total		17	17	17

09890551-080101

[illegible][illegible][illegible][illegible]

CLAIMS

What is claimed is:

5 1. A nucleic acid primer comprising an oligonucleotide that selectively hybridizes to a highly conserved region of a nucleic acid molecule of HIV-1 between nucleotide positions 4550 and 5126 or 7746 and 8459 of the HXB2 strain.

10 2. The primer of Claim 1 wherein the oligonucleotide hybridizes to a region of the *env* gene of HIV-1 between nucleotide positions selected from the group consisting of 7746 to 7772; 7817 to 7844; 8220 to 8258; 8432 to 8459; 7789 to 7816; 8347 to 8374; 7850 to 7879; 8265 to 8294; and 8281 to
15 8310.

20 3. The primer of Claim 1 wherein the oligonucleotide hybridizes to a region of the *pol* gene of HIV-1 between nucleotide positions selected from the group consisting of 4550 to 4625; 4626 to 4753; 4754 to 4984; 4985 to 5126; 4596 to 4625; 4724 to 4753; 4956 to 4984; and 5051 to 5080.

25 4. The primer of Claim 1 having a length of 18-40 nucleotides.

30 5. The primer of Claim 1 wherein the oligonucleotide has a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and conservative substitutions thereof.

6. A method of detecting HIV-1 groups M, N and O and SIVcpz in a biological sample comprising

combining the sample with a first primer under selective hybridization conditions for the selective hybridization of the first primer to HIV-1 nucleic acids in the sample, wherein the first primer comprises an oligonucleotide that selectively hybridizes to a highly conserved region of the nucleic acid molecule of HIV-1 between nucleotide positions 4550 and 5126 or 7746 and 8459 of the HXB2 strain; and

detecting hybridization of the primer to HIV-1 nucleic acids,

wherein detection of hybridization of the primer to HIV-1 nucleic acids indicates the presence of HIV-1 in the sample.

7. The method of Claim 6 wherein the first primer hybridizes to a first region of the *env* gene of HIV-1 between nucleotide positions selected from the group consisting of HIV-1 between nucleotide positions selected from the group consisting of 7746 to 7772; 7817 to 7844; 8220 to 8258; 8432 to 8459; 7789 to 7816; 8347 to 8374; 7850 to 7879; 8265 to 8294; and 8281 to 8310.

8. The method of Claim 6 wherein the first primer hybridizes to a first region of the *pol* gene of HIV-1 between nucleotide positions selected from the group consisting 4550 to 4625; 4626 to 4753; 4754 to 4984; 4596 to 4625; 4724 to 4753; and 4956 to 4984; and 8265 to 8294.

9. The method of Claim 6 wherein the oligonucleotide has a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and conservative substitutions thereof.

10. The method of Claim 6 further comprising the step of combining the sample with a second primer under selective hybridization conditions for the selective hybridization of the second primer to HIV-1 nucleic acids in the sample, wherein the second primer comprises an oligonucleotide that selectively hybridizes to a second highly conserved region of the nucleic acid molecule of HIV-1 between nucleotide positions 4550 and 5126 or 7746 and 8459 of the HXB2 strain, wherein the first and second primers are a first primer pair, and wherein the primer pair and the sample are incubated under nucleic acid amplification conditions to amplify HIV-1 nucleic acids in the sample.

11. The method of Claim 10 wherein the second primer hybridizes to a second region of the *env* gene of HIV-1 between nucleotide positions selected from the group consisting of 7746 to 7772; 7817 to 7844; 8220 to 8258; 8432 to 8459; 7789 to 7816; 8347 to 8374; 7850 to 7879; 8265 to 8294; and 8281 to 8310.

12. The method of Claim 10 wherein the second primer hybridizes to a second region of the *pol* gene of HIV-1 between nucleotide positions selected from the group consisting of 4550 to 4625; 4626 to 4753; 4754 to 4954; 4885 to 5126; 4596 to 4625; 4724 to 4753; 4956 to 4984; and 5051 to 5080.

13. The method of Claim 10 wherein the second primer has a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and conservative substitutions thereof.

14. The method of Claim 10 wherein the first primer pair comprises a forward primer and a reverse primer, wherein the forward primer comprises the nucleotide sequence of SEQ ID NO:1 and the reverse primer comprises the nucleotide sequence of SEQ ID NO:2, or wherein the forward primer comprises the nucleotide sequence of SEQ ID NO:6 and the reverse primer comprises the nucleotide sequence of SEQ ID NO:7.

15. The method of Claim 10 further comprising a second primer pair, wherein the first and second primer pairs are nested.

16. The method of Claim 15 wherein the second primer pair comprises a forward primer and a reverse primer, wherein the forward primer comprises the nucleotide sequence of SEQ ID NO:3 and the reverse primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5, or wherein the forward primer comprises the nucleotide sequence of SEQ ID NO:8 and the reverse primer comprises the nucleotide sequence of SEQ ID NO:9.

17. A method for detecting HIV-1 group N or chimpanzee SIV in a biological sample comprising

combining the sample with a first primer under selective hybridization conditions for the selective hybridization of the first primer to HIV-1 or chimpanzee SIV nucleic acids in the sample, wherein the first primer comprises the nucleotide sequence of SEQ ID NO:5; SEQ ID NO:6, SEQ ID NO:7; SEQ ID NO:8, and SEQ ID NO:9 and


detecting hybridization of the primer to HIV-1 or chimpanzee SIV nucleic acids,


wherein detection of hybridization of the primer to HIV-1 or chimpanzee SIV nucleic acids indicates the presence of HIV-1 or chimpanzee SIV in the sample.

5 18. The method of Claim 17 further comprising a second primer that hybridizes to a second highly conserved region of the nucleic acid molecule between nucleotide positions 4450 and 5126 or 7746 and 8459 of the HXB2 strain of HIV-1, wherein the first and second primers are a primer pair, and wherein the primer pair and the sample are incubated under nucleic acid amplification conditions to amplify HIV-1 nucleic acids in the sample.

10 19. The method of Claim 18 wherein the second primer has a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and conservative substitutions thereof.

T0T000" T5506860





DECLARATION FOR PATENT APPLICATION

(X) Original () Supplemental () Substitute () PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O,**" which is described and claimed in the specification

(check one) ☐ which is attached hereto, or
 ☐ which was filed on , as Application Serial No. and with amendments through
 (if applicable), or
 ☒ in International Application No. PCT/US00/02498, filed February 1, 2000, and as
 amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATIONS: (ENTER BELOW IF APPLICABLE)			PRIORITY CLAIMED (MARK APPROPRIATE BOX BELOW)	
APP. NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	YES	NO
PCT/US00/02498	PCT	1 February 2000	X	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/118,357	3 February 1999

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Renu B. Lal

Inventor's signature: *Renu Lal*

Date: 7.25.01

Residence: 2070 Asgard Court, Atlanta, Georgia 30345 GA

Post Office Address: 2070 Asgard Court, Atlanta, Georgia 30345

Citizenship: India

Full name of second inventor: Danuta Pieniazek

Inventor's signature: *Danuta*

Date: 7/25/01

Residence: 420 Hunt River Way, Suwanee, Georgia 30024 GA

Post Office Address: 420 Hunt River Way, Suwanee, Georgia 30024

Citizenship: United States

380 Full name of third inventor: Chunfu Yang

Inventor's signature: _____

Date: 7/25/01

Residence:

440 Rams Way, Tucker, Georgia 30084 GA

Post Office Address:

440 Rams Way, Tucker, Georgia 30084

Citizenship:

Canada

0989051.080101

SEQUENCE LISTING

<110> Lal, Renu B.

Pieniazek, Danuta

Yang, Chunfu

Owen, Sherry M.

Fridlund, Carol

<120> Methods and Reagents for Molecular Detection of HIV-1

Groups M, N and O

<130> 03063-0491

<140>

<141>

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for
HIV-1

09890551-000101

2

<400> 1

tcttaggagc agcaggaagc actatggg

28

<210> 2

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer
for HIV-1

<400> 2

aacgacaaag gtgagtatcc ctgcctaa

28

<210> 3

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for
HIV-1

<400> 3

acaattattg tctggtatag tgcaacagca

30

T.01.090" T.01.090" T.01.090"

3

<210> 4

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer
for HIV-1

<400> 4

ttaaacctat caagcctcct actatcatta

30

<210> 5

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: alternate
reverse primer for HIV-1

<400> 5

tcctactatc ttaatgaata tttttatata

30

<210> 6

<211> 30

09/890551-0001

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for
HIV-1

<400> 6

agtgctgcag ttaaggcagc ctgttggtgg

30

<210> 7

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer
for HIV-1

<400> 7

ctacctgccca gacaatcatc acctgccatc

30

<210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

09890551 090104

<220>

<223> Description of Artificial Sequence: primer for
HIV-1

<400> 8

aagagatcaa gctgaacatc ttaagacagc

30

<210> 9

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer for HIV-1

<400> 9

tgtattacta ctgccccttc acctttcca

29

09/890551-00101

09/890551

1

JC05 Rec'd PCT/FTO 01 AUG 2001

SEQUENCE LISTING

<110> The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services

Lal, Renu B.
Pieniazek, Danuta
Yang, Chunfu

<120> Methods and Reagents for Molecular Detection of HIV-1 Groups M, N and O

<130> 14114.0346U2

<150> PCT/US00/02498

<151> 2000-02-01

<150> 60/118,357

<151> 1999-02-03

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for HIV-1

<400> 1

tcttaggagc agcaggaagc actatggg

28

<210> 2

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer for HIV-1

<400> 2

aacgacaaag gtgagtatcc ctgcctaa

28

<210> 3

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for HIV-1

<400> 3

acaattattg tctggtatag tgcaacagca

30

09/890551 "0304"

<210> 4
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: reverse primer
 for HIV-1

<400> 4
 ttaaacttat caagcctcct actatcatta 30

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: alternate
 reverse primer for HIV-1

<400> 5
 tcctactatc ttaatgaata tttttatata 30

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for
 HIV-1

<400> 6
 agtgctgcag ttaaggcagc ctgttggtgg 30

<210> 7
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer
 for HIV-1

<400> 7
 ctacctgcca gacaatcatc acctgccatc 30

<210> 8
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for
 HIV-1

<400> 8
 aagatatcaa gctgaacatc ttaagacagc 30

<210> 9
<211> 29
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer for HIV-1

<400> 9
tgtattacta ctgccccttc acctttcca

29

09090651 080404